4-(4-chlorophenyl)-1-[(3E)-3-[9-(2-hydroxy-2-methylpropoxy)-5H-[1]benzoxepino[3,4-b]pyridin-11-ylidene]propyl]piperidin-4-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(4-chlorophenyl)-1-[(3E)-3-[9-(2-hydroxy-2-methylpropoxy)-5H-[1]benzoxepino[3,4-b]pyridin-11-ylidene]propyl]piperidin-4-ol
• 化学式: C₃₁H₃₅ClN₂O₄
• 分子量: 535.1
• InChiKey: FNQRMTZXWKUARL-KXEZBXAJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  75
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• CCR1 Inhibitors useful for the treatment of multiple myeloma and other disorders
  申请人：Veiby Ole Petter

  公开号：US20090286823A1

  公开（公告）日：2009-11-19

  The invention relates to the use of inhibitors of CCR1 for the treatment of cancers and osteolytic bone disorders. In some embodiments, the invention relates to methods for the treatment of multiple myeloma, smoldering multiple myeloma and secondary bone cancers.
• CCR1 INHIBITORS USEFUL FOR THE TREAMENT OF MULTIPLE MYELOMA AND OTHER DISORDERS
  申请人：Veiby Ole Petter

  公开号：US20130040979A1

  公开（公告）日：2013-02-14

  The invention relates to the use of inhibitors of CCR1 for the treatment of cancers and osteolytic bone disorders. In some embodiments, the invention relates to methods for the treatment of multiple myeloma, smoldering multiple myeloma and secondary bone cancers.